Skip to main content
Signal8

Chimeric Therapeutics Limited (CHMMF)

Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer. Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies. Another key program, CHM 1101 (a CLTX CAR T-cell therapy), is also in Phase I development, specifically targeting patients with recurrent or progressive glioblastoma that expresses MMP2. Beyond these lead programs, the company is actively developing a range of other innovative therapies. These include CHM 0301 for various blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK), both designed to combat solid tumors. The CLTX CAR T-cell therapy, CHM 1101, is additionally being explored for indications such as melanoma, colorectal, and prostate cancers. Furthermore, CHM 2101 (CDH17 CAR T) is under development for neuroendocrine, colorectal, pancreatic, and gastric cancers. Established in 2020, Chimeric Therapeutics Limited maintains its headquarters in Carlton, Australia.

Sector: Biotechnology

Industry: Biotechnology

Chimeric Therapeutics Limited logo

Chimeric Therapeutics Limited

OTC:CHMMFHealthcare
Mkt Cap-
EV-
Float26.23M
O/S41.04M
Inst Own-
Net Cash/Sh+$0.00
Dilution
Financials Summary
Revenue$0
Net Income-$12.69M
Total Assets$863K
Free Cash Flow$0
Debt & Equity
Total Debt$459K
Total Equity-$5.21M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
2-year cumulative
1:100

Nasdaq bars a compliance period at 1:250

  1. 1:100Reverse split
    Apr 22, 2026100 shares → 1
Balance Sheet Details
Assets$863K
Liabilities$6.07M
Accounts Receivable$20K
Accounts Payable$3.64M
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$172K
Income Statement
PeriodFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
CurrencyUSDUSDUSDUSDUSDUSDUSD
Period Ending2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-30
Revenue$0$2.68M$0$3.04M$1.77M$0$0
YoY Growth---72.2%---
Cost of Revenue$0$572K$3K$0$642K$572K$0
Gross Profit$0$2.11M-$3K$3.04M$1.13M-$572K$0
Gross Margin-78.7%-100.0%63.7%--
Research and Development$2.3M$6.6M$7.53M$9.75M$4.13M$2.55M$0
Selling, General, and Administrative$3.33M$4.76M$6.46M$8.06M$7.48M$4.17M$43K
Other$0$959K$0$2.12M$0$3.49M$0
Total Operating Expenses$5.64M$12.32M$14M$19.92M$11.61M$10.21M$43K
Operating Income (EBIT)-$5.64M-$10.21M-$14M-$16.94M-$10.2M-$10.21M-$43K
Operating Margin--380.8%--556.6%-576.7%--
Interest Expense$0$143K$224K$523K$433K$4K$0
Interest Income$26K$32K$82K$19K$9K$2K$0
Other Income (Expense)-$7.04M$3.24M-$348K-$223K-$424K-$2K$2
Income Before Tax (EBT)-$12.68M-$6.97M-$14.35M-$17.17M-$10.63M-$10.21M-$43K
Income Tax Expense$15K$75K-$5.88M$63K$111K$0$0
Net Income-$12.69M-$7.05M-$8.47M-$17.23M-$10.74M-$10.21M-$43K
Net Income Margin--262.8%--566.0%-607.5%--
Supplementary Data
EPS-0.61-0.77-1.80-5.89-4.42-4.64-0.02
Diluted EPS-0.61-0.77-1.80-5.89-4.42-4.64-0.02
Weighted Average OS30.85M13.52M6.96M4.33M3.60M3.26M3.43M
EBITDA-$5.64M-$6.13M-$7.58M-$16.23M-$9.2M-$9.64M$104K
EBITDA Margin--228.7%--533.0%-520.5%--
Balance Sheet
PeriodFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
CurrencyUSDUSDUSDUSDUSDUSDUSD
Period Ending2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-30
Assets
Current Assets
Cash and Cash Equivalents$540K$3.89M$2.06M$1.6M$12.42M$15.14M$68
Short-Term Investments$0$0$0$0$0$0$0
Cash and Short-Term Investments$540K$3.89M$2.06M$1.6M$12.42M$15.14M$68
Accounts Receivable$20K$3.08M$59K$4.5M$27K$16K$0
Inventory$0$0$0$0$0$0$0
Other Current Assets$132K$147K$56K$223K$1.86M$156K$0
Total Current Assets$691K$7.11M$2.18M$6.32M$14.3M$15.31M$68
Long-Term Assets
Property, Plant & Equipment Net$0$0$463$4K$11K$9K$0
Goodwill$0$0$0$0$0$0$0
Intangible Assets$172K$7.46M$8.11M$8.77M$9.22M$9.34M$9.34M
Long-Term Investments$0$0$27K$27K$27K$0$0
Deferred Tax Assets$0$0$0$0$0$0$0
Other Long-Term Assets$0$0$0$0$0$0$0
Total Long-Term Assets$172K$7.46M$8.14M$8.8M$9.26M$9.35M$9K
Other Assets$0$0$0$0$0$0-$9.34M
Total Assets$863K$14.57M$10.32M$15.12M$23.57M$24.67M$68
Liabilities
Current Liabilities
Accounts Payable$3.64M$4.44M$2.16M$5M$3.18M$1.38M$0
Short-Term Debt$459K$0$2.43M$0$0$0$23K
Current Income Tax Payable$0$0$0$0$0$0$0
Current Unearned Revenue$0$0$0$0$0$0$0
Other Current Liabilities$1.74M$2.53M$2.64M$2.62M$1.79M$2.92M$20
Total Current Liabilities$6M$9.87M$9.25M$9.93M$6.1M$4.97M$43
Long-Term Liabilities
Long-Term Debt$0$0$0$0$0$0$0
Long-Term Unearned Revenue$0$0$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0$0$0
Other Long-Term Liabilities$76K$3.37M$1.83M$1.37M$103K$2.72M$0
Total Long-Term Liabilities$76K$3.37M$1.83M$1.37M$103K$2.72M$0
Other Liabilities$0$0-$2.43M$0$0$0$0
Total Liabilities$6.07M$13.24M$8.65M$11.29M$6.2M$7.69M$43K
Stockholders' Equity
Preferred Stock$0$0$0$0$0$0$0
Common Stock$54.26M$47.41M$42.91M$36.44M$35M$25.25M$68
Retained Earnings-$63.81M-$51.58M-$44.97M-$38.36M-$20.85M-$10.26M-$43K
Comprehensive Income & Other$4.34M$5.5M$3.73M$5.75M$3.22M$1.99M$0
Other Stockholders' Equity$4.34M$5.5M$3.73M$5.75M$3.22M$1.99M-$1
Total Equity-$5.21M$1.33M$1.67M$3.82M$17.37M$16.98M-$43K
Minority Interest$0$0$0$0$0$0$0
Total Liabilities and Equity$863K$14.57M$10.32M$15.12M$23.57M$24.67M$67
Supplementary Data
Total Debt$459K$0$2.43M$0$0$0$23K
Net Debt-$81K-$3.89M$366K-$1.6M-$12.42M-$15.14M$23
Cash Flow Statement
PeriodFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
CurrencyUSDUSDUSDUSDUSDUSDUSD
Period Ending2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-30
Operating Activities
Net Income-$12.69M-$7.05M-$8.47M-$17.51M-$10.74M-$10.21M-$43K
Depreciation & Amortization$0$697K$731K$652K$642K$572K$104K
Deferred Income Tax$0$0$0-$1.02M-$4.99M-$832K$0
Stock-Based Compensation$0$734K$604K$2.24M$2.14M$1.42M$0
Changes in Working Capital:
  Accounts Receivable$0-$9K$2.41M-$671K-$1.78M-$16K$0
  Inventory$0$0$0$0$0$0$0
  Accounts Payable$0$0$0$3.2M$218K$1.75M$0
  Other Working Capital$0-$136K$10K$68K$67K-$156K$20K
Total Working Capital Change$0-$145K$2.42M$2.6M-$1.49M$1.58M$20K
Other Non-Cash Items$5.42M$845K-$380K$2.01M$5.55M$1.5M-$104K
Net Cash from Operating-$7.28M-$4.92M-$5.09M-$11.02M-$8.89M-$5.97M-$23K
Investing Activities
Capital Expenditures-$168K$0$0-$76K-$363K-$3.59M$0
Acquisitions$0$0$0$0$0$0$0
Purchases of Investments$0$0$0$0-$27K$0$0
Sales of Investments$0$0$0$0$0$0$0
Other Investing Activities$0$0$0-$76K$9K$2K$0
Net Cash from Investing-$168K$0$0-$76K-$382K-$3.58M$0
Financing Activities
Debt Repaid$607K-$1.54M$1.5M$2.76M$23K-
Common Stock Issuance$5.33M$5.54M$7.93M$1.74M$10.07M$24.72M$68
Common Stock Repurchases$0$0-$808K-$60K-$884K$0$0
Dividends Paid$0$0$0$0$0$0$0
Other Financing Activities-$617K$6.79M-$7K-$7K-$1.89M-$6K$23K
Net Cash from Financing$4.1M$6.79M$5.58M$171K$6.42M$24.69M$23K
Forex Effect$188K-$44K-$19K$98K$110K$6K$0
Net Change in Cash-$3.15M$1.83M$466K-$10.82M-$2.72M$15.14M$68
Supplementary Data
Operating Cash Flow-$7.28M-$4.92M-$5.09M-$11.02M-$8.89M-$5.97M-$23K
Capital Expenditure$7.28M$0$0-$76K-$363K-$3.59M$0
Free Cash Flow$0-$4.92M-$5.09M-$11.1M-$9.25M-$9.56M-$23K
Cash at Beginning$3.69M$2.06M$1.6M$12.42M$15.14M$68$0
Cash at End$540K$3.89M$2.06M$1.6M$12.42M$15.14M$68